X

JAMA Oncology

JAMA Oncology
Oncology’s “Hockey Stick” Moment for the Cost of Cancer Drugs—The Climate Is About to Change
JAMA Oncology
Progressive Dry Cough in a Patient With ROS1-Rearranged Lung Adenocarcinoma Undergoing Crizotinib Therapy
JAMA Oncology
Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic M...
JAMA Oncology
Early Detection of Human Papillomavirus–Driven Oropharyngeal Cancer Using Serology From the Study of Prevention of Anal Cancer
JAMA Oncology
Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advan...
JAMA Oncology
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sora...
JAMA Oncology
Safety of Anti–PD-L1 Inhibition in HIV-1–Infected Patients With Cancer
JAMA Oncology
Hospital Deaths a Poor Quality Metric for Patients With Cancer
JAMA Oncology
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial

In this nonrandomized phase 1/2 clinical trial of 37 patients with advanced sarcoma, the combination of doxorubicin and pembrolizumab was well tolerated.

JAMA Oncology
Safety of Anti–PD-L1 Inhibition in HIV-1–Infected Patients With Cancer—Reply
JAMA Oncology
Subscribe to JAMA Oncology

source list reference

#7d60d9
#2694a4
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#42fc9a
#cc529a
#c59445
#c8cc0c
#e8085a
#97d1a0
#b61f77
#a153ac
#e7f6e3
#9a8c2c
#a9c507
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#49cde9
#c20fce
#d95d39